Company News | Health Benefits
Jim Whelpley to speak on public plan OPEB
Jim Whelpley will speak on public sector OPEB strategies and valuation issues at the virtual Conference of Consulting Actuaries on May 9.
Read more
Stay up to date on the issues impacting the industry and be the first to hear about news and changes at Rael & Letson.
Jim Whelpley will speak on public sector OPEB strategies and valuation issues at the virtual Conference of Consulting Actuaries on May 9.
Read moreLower-cost oral GLP-1 weight loss drugs are changing the conversation around coverage for self-funded health plans. This insight examines the clinical benefits, financial considerations, and long-term challenges plan sponsors should evaluate before making coverage decisions.
Read moreA recent healthcare transparency study reveals wide disparities in hospital prices paid by private health plans across the U.S.—with private payers often paying much more that Medicare.
Read moreMental health challenges are increasingly affecting both participants and health plans, driving higher healthcare costs, missed work, and reduced productivity. This insight explores how Trusts can better support mental health through accessible plan design, early intervention resources, and ongoing communication that encourages participants to seek help before reaching a crisis point.
Read moreResearch shows that health care utilization—not just high prices—is the main driver of spending variation across U.S. counties. Learn how plan sponsors can address both cost and volume to improve value, and why local patterns matter more than ever.
Read moreParticipants can't benefit from information they never receive. Learn how a multi-channel communication strategy—supported by accurate contact information—helps multiemployer health plans improve engagement, increase awareness of available benefits, and ensure important health information reaches participants when it matters most.
Read moreWe are excited to welcome Martin Fornataro, Pharm.D., to our PBM Consulting team.
Read moreAfter a wave of FDA approvals, annual spending on CGTs is estimated to increase from $5.15 billion in 2020 to $25.3 billion in 2026! What does this mean for your plan?
Read moreWhy can't an actuary make up any number for a retiree health valuation liability - what's it matter?! Learn why it does matter if the actuary wants to stay an actuary.
Read more